Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
AssigneeDelinia, Inc.
InventorJeffrey Greve
Life of this patent
Estimating the term…
Abstract
This invention provides for a fusion protein between an IL2αβγ Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein using a linker. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2αβγ form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein.
Claims11
A method for treating an autoimmune disease, the method comprising administering to a subject in need thereof a therapeutically-effective amount of a pharmaceutical composition comprising a fusion protein comprising:
- a. a human IL-2 variant protein domain comprising human IL-2 with a substitution selected from the group consisting of:
- N88R, N88G, D20H, C125S, Q126L, and Q126F;
- b. a peptide linker domain;
- and
- c. an IgG Fc protein domain, wherein each domain has an amino-terminus (N-terminus) and a carboxy terminus (C-terminus);
- and wherein the fusion protein is configured so that the C-terminus of the human IL-2 variant protein domain is fused through a peptide bond to the N-terminus of the peptide linker domain, and the N-terminus of the IgG Fc protein domain is fused through a peptide bond to the C-terminus of the peptide linker domain, and
- wherein the autoimmune disease is selected from the group consisting of Graft-vs-Host Disease, Pemphigus Vulgaris, Systemic Lupus Erythematosus, Scleroderma, Ulcerative Colitis, Crohn's Disease, Psoriasis, Type 1 Diabetes, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Alopecia Areata, Uveitis, Neuromyelitis Optica, and Duchenne Muscular Dystrophy.
Dependencies are inferred from the claim text.